Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. announced that its Board of Directors accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. She had served as a Class director and was a member of the Nominating and Corporate Governance Committee.
The Board resolved to reduce its size to nine directors upon her resignation. According to the company, Dr. Haller’s decision was not the result of any dispute or disagreement regarding the company’s operations, policies, or practices, and the Board expressed appreciation for her service.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
|
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
(
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which
Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 6, 2026, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. The Board has resolved to reduce its size to nine directors immediately upon Dr. Haller’s resignation. Dr. Haller was a Class II director of the Board and served serve as a member of the Nominating and Corporate Governance Committee. A copy of Dr. Haller’s resignation letter is included as Exhibit 99.1 to this Current Report on Form 8-K.
Dr. Haller’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.
The Company and Board thank Dr. Haller for her service and are grateful for her valuable contributions during her tenure.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Resignation letter dated March 6, 2026, from Dr. Julia Haller. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Outlook Therapeutics, Inc. | ||
| Date: March 11, 2026 | By: | /s/ Lawrence A. Kenyon |
| Lawrence A. Kenyon | ||
| Chief Financial Officer | ||
Exhibit 99.1
 |
840 Walnut Street | Julia A. Haller, MD |
| Suite 1510 Philadelphia, PA 19107 |
Ophthalmologist-in-Chief and William Tasman, MD, Endowed Chair | |
| Professor and Chair of Ophthalmology Sidney Kimmel Medical College at Thomas Jefferson University | ||
| Jhaller@willseye org | ||
| T 215-928-3073 |
March 6, 2026
Mr. Bob Jahr
Chief Executive Officer
Outlook Therapeutics, Inc.
111S.
Wood Ave, Unit #100
Iselin, NJ 08830
Dear Bob,
It has been a real honor and pleasure to serve on the Board of Directors of Outlook Therapeutics for the last few years.
As you are aware, I have taken on new responsibilities as CEO here at Wills Eye Hospital. As a result, time constraints are forcing me to limit my outside commitments.
To this end, and with regret and respect, I will need to step down from the Outlook Therapeutics board effective March 10, 2026.
I am so appreciative of the opportunity over the last years to work with you and the tremendous team at Outlook to bring new therapies to patients with unmet needs.
I wish the company the very best of luck. You can count on my continued support.
With warmest regards,
 | |
| Julia A. Haller, MD | |
| Chief Executive Officer and Ophthalmologist-in-Chief |
Filing Exhibits & Attachments
4 documents